Evidence map›Paper›PMID 37014891›Full record

ArticlePloS one2023

BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images.

Ziyu Su, Muhammad Khalid Khan Niazi, Thomas E Tavolara, Shuo Niu, Gary H Tozbikian, Robert Wesolowski, Metin N Gurcan

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Ziyu SuCenter for Biomedical Informatics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.ORCID 0000-0001-9600-3078
Muhammad Khalid Khan NiaziCenter for Biomedical Informatics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.
Thomas E TavolaraCenter for Biomedical Informatics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.
Shuo NiuDepartment of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.
Gary H TozbikianDepartment of Pathology, The Ohio State University, Columbus, Ohio, United States of America.
Robert WesolowskiComprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, Ohio, United States of America.
Metin N GurcanCenter for Biomedical Informatics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common malignancy in women, with over 40,000 deaths annually in the United States alone. Clinicians often rely on the breast cancer recurrence score, Oncotype DX (ODX), for risk stratification of breast cancer patients, by using ODX as a guide for personalized therapy. However, ODX and similar gene assays are expensive, time-consuming, and tissue destructive. Therefore, developing an AI-based ODX prediction model that identifies patients who will benefit from chemotherapy in the same way that ODX does would give a low-cost alternative to the genomic test. To overcome this problem, we developed a deep learning framework, Breast Cancer Recurrence Network (BCR-Net), which automatically predicts ODX recurrence risk from histopathology slides. Our proposed framework has two steps. First, it intelligently samples discriminative features from whole-slide histopathology images of breast cancer patients. Then, it automatically weights all features through a multiple instance learning model to predict the recurrence score at the slide level. On a dataset of H&E and Ki67 breast cancer resection whole slides images (WSIs) from 99 anonymized patients, the proposed framework achieved an overall AUC of 0.775 (68.9% and 71.1% accuracies for low and high risk) on H&E WSIs and overall AUC of 0.811 (80.8% and 79.2% accuracies for low and high risk) on Ki67 WSIs of breast cancer patients. Our findings provide strong evidence for automatically risk-stratify patients with a high degree of confidence. Our experiments reveal that the BCR-Net outperforms the state-of-the-art WSI classification models. Moreover, BCR-Net is highly efficient with low computational needs, making it practical to deploy in limited computational settings.

Indexed as

Breast NeoplasmsDeep LearningBreastFemaleHumansKi-67 AntigenRiskKi-67 Antigen

Identifiers

PMID37014891
PMCPMC10072418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.